Soft Tissue Sarcomas in the Precision Medicine Era: New Advances in Clinical Practice and Future Perspectives

Overview

Journal Radiol Med

Specialty Radiology

Date 2018 Apr 6

PMID 29619613

Citations 6

Authors

Giuseppe Badalamenti

Carlo Messina

Ida De Luca

Emmanuela Musso

Alessandra Casarin

Lorena Incorvaia

Affiliations

Soon will be listed here.

Abstract

Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumours derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combinations has been able to improve clinical benefits, prognosis is still poor and STSs represent an important unmet medical need. Continuous advances in cancer genetics and genomics have contributed to change management paradigms of STSs as it occurred for other solid tumours. Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumour progression. The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs.

Citing Articles

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement.

Badalamenti G, Incorvaia L, Algeri L, Bonasera A, Dimino A, Scalia R Ther Adv Med Oncol. 2022; 14:17588359221086829.

PMID: 35356263 PMC: 8958699. DOI: 10.1177/17588359221086829.

Delta radiomics: a systematic review.

Nardone V, Reginelli A, Grassi R, Boldrini L, Vacca G, DIppolito E Radiol Med. 2021; 126(12):1571-1583.

PMID: 34865190 DOI: 10.1007/s11547-021-01436-7.

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment.

Nardone V, Boldrini L, Grassi R, Franceschini D, Morelli I, Becherini C Cancers (Basel). 2021; 13(14).

PMID: 34298803 PMC: 8303203. DOI: 10.3390/cancers13143590.

Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe.

Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D Insights Imaging. 2021; 12(1):76.

PMID: 34114094 PMC: 8192650. DOI: 10.1186/s13244-021-01017-2.

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.

Jardim D, Millis S, Ross J, Woo M, Ali S, Kurzrock R Oncologist. 2020; 26(1):e78-e89.

PMID: 32885893 PMC: 7794175. DOI: 10.1634/theoncologist.2020-0509.

References

Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B . Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012; 23(12):3171-3179. DOI: 10.1093/annonc/mds143. View

Zhang Z, Ren X, Lu X, Wang D, Hu X, Zheng Y . GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Lett. 2016; 375(1):172-178. DOI: 10.1016/j.canlet.2016.02.017. View

Bielack S, Smeland S, Whelan J, Marina N, Jovic G, Hook J . Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good.... J Clin Oncol. 2015; 33(20):2279-87. PMC: 4486345. DOI: 10.1200/JCO.2014.60.0734. View

Mouridsen H, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder J . Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987; 23(10):1477-83. DOI: 10.1016/0277-5379(87)90089-7. View

Chou A, Kleinerman E, Krailo M, Chen Z, Betcher D, Healey J . Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009; 115(22):5339-48. PMC: 2783515. DOI: 10.1002/cncr.24566. View

Li C, Wang Y, Lu S, Zhang Z, Meng H, Liang L . MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α. Mol Med Rep. 2015; 12(5):7072-8. DOI: 10.3892/mmr.2015.4263. View

Ben-Ami E, Barysauskas C, Solomon S, Tahlil K, Malley R, Hohos M . Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017; 123(17):3285-3290. PMC: 5762200. DOI: 10.1002/cncr.30738. View

Ng F, Boucher S, Koh S, Sastry K, Chase L, Lakshmipathy U . PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic,.... Blood. 2008; 112(2):295-307. DOI: 10.1182/blood-2007-07-103697. View

Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer H, van Hoesel Q . Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the.... J Clin Oncol. 2000; 18(14):2676-84. DOI: 10.1200/JCO.2000.18.14.2676. View

10.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B . Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005; 4(3):369-79. DOI: 10.1158/1535-7163.MCT-04-0114. View

11.

Hensley M, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C . Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20(12):2824-31. DOI: 10.1200/JCO.2002.11.050. View

12.

Wagner A, Kindler H, Gelderblom H, Schoffski P, Bauer S, Hohenberger P . A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017; 28(3):541-546. PMC: 5391707. DOI: 10.1093/annonc/mdw659. View

13.

Judson I, Verweij J, Gelderblom H, Hartmann J, Schoffski P, Blay J . Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4):415-23. DOI: 10.1016/S1470-2045(14)70063-4. View

14.

Rosenberg S, Lotze M, Yang J, Aebersold P, Linehan W, Seipp C . Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989; 210(4):474-84; discussion 484-5. PMC: 1357927. DOI: 10.1097/00000658-198910000-00008. View

15.

George S, Merriam P, Maki R, Van Den Abbeele A, Yap J, Akhurst T . Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009; 27(19):3154-60. PMC: 2716937. DOI: 10.1200/JCO.2008.20.9890. View

16.

Vlenterie M, Litiere S, Rizzo E, Marreaud S, Judson I, Gelderblom H . Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016; 58:62-72. DOI: 10.1016/j.ejca.2016.02.002. View

17.

LAWRENCE Jr W, DONEGAN W, Natarajan N, Mettlin C, Beart R, Winchester D . Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987; 205(4):349-59. PMC: 1492738. DOI: 10.1097/00000658-198704000-00003. View

18.

Jo V, Fletcher C . WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2):95-104. DOI: 10.1097/PAT.0000000000000050. View

19.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

20.

Heinrich M, Maki R, Corless C, Antonescu C, Harlow A, Griffith D . Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33):5352-9. PMC: 2651076. DOI: 10.1200/JCO.2007.15.7461. View